| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 10/02/2008 | WO2008051826A3 Purines as pkc-theta inhibitors |
| 10/02/2008 | WO2008050698A3 Agent for prophylaxis or treatment of alcohol dependence or drug dependence |
| 10/02/2008 | WO2008049902A3 Macrocyclic quinazoline derivatives as vegfr3 inhibitors |
| 10/02/2008 | WO2008042841A3 Docetaxel compositions |
| 10/02/2008 | WO2008039418A3 Acylated piperidine derivatives as melanocortin-4 receptor modulators |
| 10/02/2008 | WO2008034142A3 Synthesis, methods of using, and compositions of cycloalkylmethylamines |
| 10/02/2008 | WO2008033655A3 Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy |
| 10/02/2008 | WO2008031065A3 Formulation and method for a sunblock for animals |
| 10/02/2008 | WO2008030524A3 Liquid pharmaceutical formulations for oral administration of a cgrp antagonist |
| 10/02/2008 | WO2008026125A3 Anti cancer use of caffeic acid and derivatives |
| 10/02/2008 | WO2008025965A3 Retinoid compounds and their use |
| 10/02/2008 | WO2008024139A3 Inhibitors of fatty acid amide hydrolase |
| 10/02/2008 | WO2008020904A3 Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures |
| 10/02/2008 | WO2008020260A3 Use of siderophores in prevention of vascular diseases, production of siderophores and qualifying siderophore containing meat-products |
| 10/02/2008 | WO2008019240A3 3, 6-bridged tylosin derivatives |
| 10/02/2008 | WO2008015429A3 Pharmaceutical compounds |
| 10/02/2008 | WO2008009076A3 Substituted pyrido(3,2-d)pyrimidines and pharmaceutical compositions for treating viral infections |
| 10/02/2008 | WO2008005479A3 Charge reversible polymers |
| 10/02/2008 | WO2008001101A3 Pharmaceutical combinations |
| 10/02/2008 | WO2007143336A3 Use of ractopamine enantiomers |
| 10/02/2008 | WO2007142755A3 Purine analogs |
| 10/02/2008 | WO2007139968A3 Triazole compounds that modulate hsp90 activity |
| 10/02/2008 | WO2007133561A3 Substituted azaspiro derivatives |
| 10/02/2008 | WO2007133076A3 Mannitol and/or proline for prevention and treatment of ageing related symptoms |
| 10/02/2008 | WO2007127137A3 Disubstituted aniline compounds |
| 10/02/2008 | WO2007121339A3 Process for the preparation of indazolyl ureas that inhibit vanilloid subtype 1 (vr1) receptors |
| 10/02/2008 | WO2007120621A3 Nonel 1,2,3,4-tetrahydroquinoline derivatives |
| 10/02/2008 | WO2007120477A3 Products containing a pheromone component |
| 10/02/2008 | WO2007120343A3 Heat shock rna and its use |
| 10/02/2008 | WO2007111864A3 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| 10/02/2008 | WO2007101400A8 Transdermal patch containing rasagiline for treatment or prophylaxis of nervous system disease and its preparation process |
| 10/02/2008 | WO2007100614A3 STABLE NON-CRYSTALLINE FORMULATION COMPRISING HMG-CoA REDUCTASE INHIBITOR |
| 10/02/2008 | WO2007075626A3 Immunostimulatory activity of palindromic immune modulatory oligonucleotides (imo tm) contiaining different lengths of palindromic segments |
| 10/02/2008 | WO2007062138A3 Methods and compositions for treating diseases targeting human prominin-1(cd133) |
| 10/02/2008 | WO2007044893A3 Compounds and methods for inhibiting hepatitis c viral replication |
| 10/02/2008 | WO2007030602A3 Treatment of b cells with il-21 and b cell activators induces granzyme b production |
| 10/02/2008 | WO2005124563A3 Compounds and kits for treating muscle disorders and methods of use thereof |
| 10/02/2008 | US20080242855 Process for Producing Flavone C Glycoside Derivatives |
| 10/02/2008 | US20080242735 Treatment method for mmp-implicated pathologies |
| 10/02/2008 | US20080242734 Amantadine therapeutic for treatment and prevention of enterovirus (EV) or encephalomyocarditis virus (EMCV) infection |
| 10/02/2008 | US20080242733 (-)-Pseudoephedrine as a sympathomimetic drug |
| 10/02/2008 | US20080242732 Administering pharmaceutical orally at dose-delivery rate sufficient to provide clinically effective blood level in portal vein, less than required for blood level in peripheral circulation to provide dose-delivery selective in liver |
| 10/02/2008 | US20080242731 Delivering a near neutral pH topical anesthetic agent in a mixture into a natural body cavity to cause a rapid onset anesthetic effect without precipitation of the anesthetic; use in uterine area; lidocaine for example |
| 10/02/2008 | US20080242730 Hydroxamic Acid Derivatives and the Preparation Method Thereof |
| 10/02/2008 | US20080242729 Retinoid X Receptor antagonists; (2E,4E,)-(1RS,2RS)-5-[2-(3,5-di-tert-butyl-2-butoxy-phenyl)-cyclopropyl]-3-methyl-penta-2,4-dienoic acid; topical or oral administration; diseases of the skin and/or mucous membranes |
| 10/02/2008 | US20080242728 gabapentin tannate to treat central nervous system disorders; used in sustained release applications and to improve certain organoleptic properties such as taste |
| 10/02/2008 | US20080242727 enhancing protein synthesis and decrease protein catabolism; combating muscle wasting associated with dieting and/or disease |
| 10/02/2008 | US20080242726 may contain both cis-clomiphene and trans-clomiphene, and the ratio of trans-clomiphene and cis-clomiphene may be greater than 71/29; extended release |
| 10/02/2008 | US20080242725 pharmaceutical ingredients susceptible to conversion to alternate polymorph forms are prepared by a process of wet granulation in which the ratios of active, fillers, and granulating liquid are controlled in order to avoid polymorphic interconversions |
| 10/02/2008 | US20080242724 ointment or eyedrops; addition of maleic acid, dissolved in a suitable organic solvent, to ibopamine base |
| 10/02/2008 | US20080242723 for treating or preventing diseases or disorders such as spasticity or gastroesophageal reflux disease; oral dosage formulation |
| 10/02/2008 | US20080242722 composition comprising a nitric oxide donating compound (e.g. 5,6-bis(nitrooxy)hexyl acetate) and cyclooxygenase-2 selective inhibitor; antiinflammatory, analgesic agent; to reduce the gastrointestinal toxicity caused by aspirin and COX-inhibitor therapy |
| 10/02/2008 | US20080242720 Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome |
| 10/02/2008 | US20080242719 Reduce tumor necrosis factor; phosphodiesterase inhibitor; antiinflammatory agents; anticancer agents; antidepressants; skin diosrders |
| 10/02/2008 | US20080242718 point-of-care platelet analyzer device optimized for neuro-psychiatric analytes; testing and software predetermines risks of developing various neuropsychiatric conditions, like depression, Parkinson's, Alzheimer's, bipolar disorder, ADD/ADHD, autism, asperger's syndrome, OCD and other anxiety disorders |
| 10/02/2008 | US20080242717 Methods for treating benign prostatic hyperplasia |
| 10/02/2008 | US20080242716 Ion Channel Modulators |
| 10/02/2008 | US20080242715 Psychological disorders such as schizophrenia and sexual disorders |
| 10/02/2008 | US20080242714 alpha -[hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1-octenyl)-2H-cyclopenta[b]furan-2-ylidene]-1H-tetrazole-5-2E-pentanenitrile; inhibits release of Th-1 cytokines while sparing expression of Th-2 cytokines; viricide; respiratory diseases associated with influenza A viruses |
| 10/02/2008 | US20080242713 alpha -[hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1-octenyl)-2H-cyclopenta[b]furan-2-ylidene]-1H-tetrazole-5-2E-pentanenitrile; inhibits release of Th-1 cytokines while sparing expression of Th-2 cytokines; multiple sclerosis, psoriasis, rheumatoid arthritis, Crohn's disease, alopecia areata |
| 10/02/2008 | US20080242712 Identification and uses of novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure |
| 10/02/2008 | US20080242711 Inhibitors of cholesterol ester transfer protein |
| 10/02/2008 | US20080242710 Controlling cell adhesion, migration, activation; antiinflammatory agents; autoimmune diseases |
| 10/02/2008 | US20080242709 2-amido-4-isoxazolyl thiazole compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| 10/02/2008 | US20080242707 Using 4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)-2-pyridinecarboxylic acid methyl amide |
| 10/02/2008 | US20080242706 neurodegenerative diseases; to remove free iron or iron accumulation in neural tissues; iron chelators; improved chemical stability, penetration through blood brain barrier; reacting 3-hydroxy-4-pyridinone/3-hydroxy-4-pyranone derivatives; 1-cyclopropyl-2-difluoromethyl-5-hydroxy-1H-pyridin-4-one |
| 10/02/2008 | US20080242705 Fluridone as an Anti-Inflammatory Agent |
| 10/02/2008 | US20080242704 selectively modulate, regulate, and/or inhibit signal transduction; potent and selective c-kit, bcr-abl and Fit-3 inhibitors; diseases like cell proliferation, metabolic, allergic, cancers, degenerative, autoimmune disorders; 4-{2-[5-(Benzothiazol-2-ylammo)-2-methyl-phenylamino]-oxazol-5-yl}-benzonitrile |
| 10/02/2008 | US20080242703 Pharmaceutical compositions for the treatment of hearing loss |
| 10/02/2008 | US20080242702 Paclitaxel enhancer compound |
| 10/02/2008 | US20080242701 Antitumor agents; anticancer agents; cytotoxic activity; angiogenesis inhibitor; leukemia; colorectal cancer; administering by mouth |
| 10/02/2008 | US20080242700 Methods and Compositions for Selectin Inhibition |
| 10/02/2008 | US20080242699 Cyclohexylamin isoquinolone derivatives |
| 10/02/2008 | US20080242698 Antiepilrptic agents; antiischemic agents; vision defects; skin disorders; muscular disorders; anticonvulsants;analgesics; Parkinson's disease; huntington's disease; amyotrophic lateral sclerosis; multiple sclerosis |
| 10/02/2008 | US20080242697 Reacting 3-quinuclidinol with 1,3-carbonyldi(1,2,4triazole) in solvent; then 1,2,3,4-tetrahydroisoqionoline; isolation; purification |
| 10/02/2008 | US20080242696 Mixing with a solvent and heating |
| 10/02/2008 | US20080242695 Certain Chemical Entities, Compositions, and Methods |
| 10/02/2008 | US20080242694 inhibition of a kinase pathway for the treatment of cancer, inflammatory, immunological and metabolic conditions; agents may target two or more kinases of the same/different family; [2-AMINO-1-(2-PHENYLETHYL)ETHYL](5-(6-ISOQUINOLYL)(1,3,4-THIADIAZOL-2-YL))AMINE |
| 10/02/2008 | US20080242693 dopamine and nicotinic acetylcholine receptors antagonist; analgesic, antidepressant, anxiolytic agent; neurodegenerative diseases, drug and nicotine abuse, obesity; 6-(5-methoxy-3-pyridinyl)-3-azabicyclo[3.3.1]non-6-ene |
| 10/02/2008 | US20080242692 Synthesis of Indenoisoquinoliniums and Methods of Use |
| 10/02/2008 | US20080242691 Aqueous Solution Preparation Containing Camptothecins |
| 10/02/2008 | US20080242690 Methods and Compositions for Promoting Bone and Joint Health |
| 10/02/2008 | US20080242689 N-aryl azaspiroalkene and azaspiroalkane compounds and methods of preparation and use thereof |
| 10/02/2008 | US20080242688 Cognition activators, Alzheimer's disease, schizophrenia |
| 10/02/2008 | US20080242687 endothelin modulators/antagonists; reduced hepatoxicity; hypotensive agents; Deuterated Pyrimidine Derivatives like 4-tert-Butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl-4-yl]-benzenesulfonamide |
| 10/02/2008 | US20080242686 Pharmaceutical compositions of lavendustin |
| 10/02/2008 | US20080242685 Chemical Compounds |
| 10/02/2008 | US20080242684 Methods of administration of adenosine a1 receptor antagonists |
| 10/02/2008 | US20080242683 Antiinflammatory agents; chronic obstructive pulminary disease |
| 10/02/2008 | US20080242682 Preventive or Therapeutic Agent for Sleep Disorder |
| 10/02/2008 | US20080242681 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors |
| 10/02/2008 | US20080242680 Agent for the prophylaxis or treatment of neurodegenerative disease |
| 10/02/2008 | US20080242679 Using 1-(2-(3-trifluoromethylphenyl)piperazin-1-yl)ethyl)2,3-dihydro-1H-benzimidazol-2-one |
| 10/02/2008 | US20080242678 Use of Flibanserin in the Treatment of Obesity |
| 10/02/2008 | US20080242677 improved pharmacological properties like metabolic stability, selectivity, bioavailability and activity; Liver-X-Receptors modulators; to treat increased lipid and cholesterol levels; 4-[4-(2,5-Dimethyl-phenyl)-piperazine-1-carbonyl]-1-(3-methoxy-benzenesulfonyl)-3-phenyl-imidazolidin-2-one |
| 10/02/2008 | US20080242676 Drug resistant Mycobacterium tuberculosis |
| 10/02/2008 | US20080242675 Prevent transplant rejection |
| 10/02/2008 | US20080242674 Medicine For Prevention or Treatment of Frequent Urination or Urinary Incontinence |
| 10/02/2008 | US20080242673 novel triazolopyrimidine derivatives like 7-(2-(4-(2,5-Difluorophenyl)piperazin-1-yl)ethyl)-2-(furan-2-yl)-7H-pyrrolo[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine; to treat central nervous system disorders like depression, Parkinson's disease; senile dementia; psychoses etc. |
| 10/02/2008 | US20080242672 Adenosine a2a receptor antagonists |